e-learning
resources
Madrid 2019
Monday, 30.09.2019
ECMO, ECCO2R and other rescue therapies in acute respiratory failure
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Tetracycline alleviates acute lung injury by inhibition of NLRP3 inflammasome
C. Bode (Bonn, Germany), K. Peukert (Bonn, Germany), J. Schewe (Bonn, Germany), C. Putensen (Bonn, Germany), E. Latz (Bonn, Germany), F. Steinhagen (Bonn, Germany)
Source:
International Congress 2019 – ECMO, ECCO2R and other rescue therapies in acute respiratory failure
Session:
ECMO, ECCO2R and other rescue therapies in acute respiratory failure
Session type:
Poster Discussion
Number:
2175
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
C. Bode (Bonn, Germany), K. Peukert (Bonn, Germany), J. Schewe (Bonn, Germany), C. Putensen (Bonn, Germany), E. Latz (Bonn, Germany), F. Steinhagen (Bonn, Germany). Tetracycline alleviates acute lung injury by inhibition of NLRP3 inflammasome. 2175
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Risk factors of adverse outcome after acute hospitalization in Idiopathic Pulmonary Fibrosis (IPF)
Related content which might interest you:
NLRP3 inflammasome conjugates with mitochondria in LPS-induced acute lung injury
Source: Virtual Congress 2020 – Cellular stress in respiratory diseases
Year: 2020
Activation of NLRP3 inflammasome is regulated by mitochondrial ROS via PI3K-HIF-VEGF pathway in acute lung injury
Source: International Congress 2015 – Novel insights into the pathobiology of acute lung injury
Year: 2015
Andrographolide inhibits the activation of NLRP3 inflammasome in patients with COPD
Source: International Congress 2018 – Preclinical pharmacology: novel targets in airway inflammation, narrowing and neural control
Year: 2018
Statins worse pulmonary fibrosis through enhancing NLRP3 inflammasome activation
Source: Annual Congress 2012 - Animal models of asthma and COPD and late-breaking abstracts on RCT in asthma and COPD
Year: 2012
Injury induced inflammasome activation leading to IL-1b and lung inflammation depends on IL-17
Source: Annual Congress 2010 - Stem cells and growth factors in lung injury
Year: 2010
The activation of NLRP3 inflammasome pathway in COPD is limited in local airways
Source: International Congress 2018 – Disease exacerbations from a molecular point of view
Year: 2018
Effect of curcumin on LPS-induced neutrophil activation and acute lung injury
Source: Annual Congress 2012 - Lung injury, respiratory muscles and mechanical ventilation
Year: 2012
Mitochondria-targeted H2S suppresses and reverses cigarette smoke-induced inflammasome activity and lung injury in experimental COPD
Source: ERS Lung Science Conference 2020
Year: 2020
A role for the inflammasome effector caspase-1 in hypoxia-induced pulmonary hypertension
Source: International Congress 2017 – Experimental PH
Year: 2017
Dipeptide HCH6-1 inhibits neutrophil activation and protects against acute lung injury by blocking FPR1
Source: International Congress 2017 – Towards better treatments for lung disease: experimental pharmacology
Year: 2017
Elevated expression of the NLRP3 inflammasome in neutrophilic asthma
Source: Eur Respir J 2014; 43: 1067-1076
Year: 2014
Cigarette smoke extract inhibits the NLRP3 inflammasome in human macrophages and impairs cell metabolism via NLRP3-independent activation of Caspase-1
Source: International Congress 2019 – Effects of environmental exposures in lung pathology and the underlying mechanisms
Year: 2019
Amifostine reduces lipopolysaccharide-induced lung dysfunction via suppression of redox-sensitive inflammatory signaling
Source: Annual Congress 2008 - Animal models of pulmonary fibrosis: mechanisms and therapies
Year: 2008
A role for PAR1 in lipopolysaccharide induced acute lung injury
Source: Annual Congress 2008 - Vascular and interstitial remodelling in chronic lung disease: therapeutic interventions on the horizon
Year: 2008
Effects of autophagy on LPS-induced lung inflammation and acute lung injury (ALI) in vitro and in vivo
Source: International Congress 2018 – Role of microbial exposure and inflammation in lung injury
Year: 2018
Hypoxia induces inflammasome activation and influx of neutrophils and T-cells in the lungs
Source: Annual Congress 2013 –Novel mechanisms in lung injury
Year: 2013
Inhibition of neutrophil apoptosis by sphingosin-1-phopsphate through the activation of neutral sphingomyelinase in acute lung injury
Source: Annual Congress 2010 - Emerging mechanisms in lung injury
Year: 2010
Pioglitazone attenuates endotoxin-induced acute lung injury by reducing neutrophil recruitment
Source: Eur Respir J 2012; 40: 416-423
Year: 2012
IL-9 protects against bleomycin-induced lethal lung injury through a prostaglandin-dependent mechanism
Source: Eur Respir J 2004; 24: Suppl. 48, 105s
Year: 2004
Enhanced expression of Robo4 ameliorates LPS-induced acute lung injury in mice
Source: Annual Congress 2011 - Acute respiratory failure
Year: 2011
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept